Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 02, Issue-02, March-April, 2026

mRNA–Nanoparticle Complexes: Pharmaceutical Engineering for Next-Gen Therapeutics

Pavani Sure[1*], N. Sandeepthi[1], N. Jhancy Laxmi Bai[2], Bodige Mounika [1], M.Srinivasa Murthy[1]

[1]Vignan Institute of Pharmaceutical Sciences, Deshmukhi, Yadadri Bhuvanagiri, Hyderabad, Telangana,508284, India
[2]MNR College of Pharmacy, Sangareddy, Fasilwadi, Telangana 502294, India

***Corresponding Author E-mail:** pavanichandra2011@gmail.com

Abstract:

mRNA–nanoparticle complexes are rapidly reshaping modern therapeutics, blending the programmability of mRNA with the precision and protection offered by advanced nanocarriers. While mRNA provides a flexible, software-like approach to generating therapeutic proteins, its fragility and immunogenicity demand sophisticated delivery systems. Nanoparticles — especially lipid, polymeric, hybrid, and bioinspired platforms — shield mRNA from enzymatic degradation, enhance cellular uptake, enable endosomal escape, and support targeted or controlled release. Recent engineering breakthroughs in microfluidics, AI-guided design, nucleoside modification, and surface functionalization have dramatically improved the stability, potency, and safety of mRNA formulations. These technologies now power applications ranging from vaccines and cancer immunotherapy to rare-disease treatments, regenerative medicine, and in vivo gene editing. Despite challenges in large-scale manufacturing, long-term safety assessment, and cold-chain dependence, ongoing innovation is pushing mRNA nanomedicine toward more durable, personalized, and globally accessible therapies. Together, mRNA–nanoparticle systems stand at the forefront of next-gen precision medicine, promising fast, customizable solutions for previously untreatable conditions.

Keywords
mRNA Therapeutics; Lipid Nanoparticles (Lnps); Polymeric Nanoparticles; Nanomedicine; RNA Delivery; Self-Amplifying Mrna; Circular RNA; Microfluidics; Targeted Delivery; Endosomal Escape; Personalized Vaccines; Cancer Immunotherapy; Regenerative Medicine; CRISPR Mrna; Pharmaceutical Engineering.

Received: Jan. 08, 2026 **Revised: Feb. 18, 2026** **Accepted: March. 24, 2026** **Published: April 10, 2026**

DOI: https://doi.org/10.64062/JPGMB.Vol2.Issue2.5

https://jpgmb.com/1/issue/archive

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. ***(https://creativecommons.org/licenses/by-nc/4.0/)***

1. Introduction

The rapid rise of mRNA therapeutics marks one of the most transformative shifts in modern medicine, reshaping everything from how we develop vaccines to how we imagine precision treatments for chronic and genetic disorders. While the COVID-19 pandemic thrust mRNA vaccines into the global spotlight, their potential was never limited to infectious diseases alone. mRNA is fundamentally a programmable biomolecule—like biological software—that can instruct cells to produce virtually any therapeutic protein, antigen, or functional molecule on demand [1-2]. This "plug-and-play" approach reduces development time, enables rapid adaptation against emerging pathogens, and supports highly personalized strategies such as neoantigen cancer vaccines tailored to each patient's tumor. But for all its promise, naked mRNA is extremely fragile. It breaks down rapidly in biological environments, suffers from inefficient cellular uptake, activates innate immune sensors, and struggles to reach target tissues intact. Without protection and a clever delivery strategy, mRNA's therapeutic potential simply can't reach the finish line [3-4].

This is where nanoparticles step in as the unsung heroes of next-gen drug delivery. Nanoparticles are engineered to shield mRNA from enzymatic degradation, facilitate its transport across biological barriers, and ensure that it reaches the cytosol—where protein translation actually happens [5-6]. By tuning their size, charge, surface chemistry, and composition, nanoparticles solve multiple challenges simultaneously: they enhance biodistribution, promote endosomal escape, modulate immune activation, and allow for controlled or targeted delivery. Lipid nanoparticles (LNPs), for example, have become the gold standard for mRNA vaccines due to their highly efficient encapsulation, biocompatibility, and ability to fuse with cellular membranes. Beyond LNPs, polymeric nanoparticles, lipid–polymer hybrids, and bioinspired vesicles are emerging as versatile platforms for more specialized applications, especially where targeting specific organs or cell types matters [7-8].

Engineering mRNA–nanoparticle complexes represents the convergence of pharmaceutical science, nanotechnology, molecular biology, and computational design. This interdisciplinary fusion enables researchers to precisely control how mRNA behaves in vivo—how long it circulates, where it accumulates, and how strongly it triggers immune responses [8-9]. The significance of this engineering goes far beyond vaccines: mRNA–nanoparticle systems are now being explored for cancer immunotherapy, genetic disease treatment, regenerative medicine, cardiology, neurology, and even protein-replacement therapies for rare disorders. As we move toward personalized medicine and on-demand biologics, engineered mRNA nanoparticles offer a route to deliver complex biological instructions reliably and safely [10-11].

The scope of this field is expanding rapidly, driven by advances in microfluidics, AI-based sequence design, novel biomaterials, and high-throughput formulation technologies. Yet despite the progress, major challenges remain—such as cold-chain dependence, long-term safety evaluation, large-scale manufacturing, and the quest for more targeted, less immunogenic nanoparticle carriers. Understanding how mRNA interacts with nanoparticles, how these complexes behave in the body, and how they can be rationally engineered is essential

for unlocking the therapeutic potential of mRNA across diverse clinical landscapes. This review explores these aspects in depth, emphasizing how pharmaceutical engineering innovations are shaping the future of mRNA-based therapeutics [12-13].

2. Fundamentals of mRNA Therapeutics

To fully appreciate the engineering behind mRNA–nanoparticle complexes, it's important to understand what makes therapeutic mRNA unique and how its structure dictates function. An mRNA molecule isn't just a random chain of nucleotides—it's a carefully designed blueprint composed of functional domains that work in harmony to ensure proper translation inside the cell. At its core, mRNA contains a 5′ cap structure that initiates ribosome binding, a 5′ untranslated region (UTR) that regulates translation efficiency, an open reading frame (ORF) that codes for the therapeutic protein, a 3′ UTR that influences stability and localization, and a poly(A) tail that protects mRNA from degradation while supporting translation [14-15]. Each component must be optimized for expression, stability, and minimal immune activation, making the design of therapeutic mRNA an engineering challenge in itself.

Modern mRNA therapeutics rely heavily on chemical and structural modifications to enhance performance. Cap analogs such as CleanCap™ or ARCA improve ribosome recruitment and protect mRNA from decapping enzymes. UTR optimization—often using naturally stable UTR sequences from highly expressed human genes—boosts translation levels. Nucleoside modifications, including pseudouridine (Ψ) and N1-methyl-pseudouridine (m1Ψ), have become critical for reducing innate immune recognition and improving protein output. Poly(A) tail engineering, including controlled tail length and incorporation of stabilizing sequences, further enhances mRNA half-life and translational capacity [16-17]. Together, these modifications transform what would otherwise be unstable and immunogenic RNA into a finely tuned therapeutic agent.

Manufacturing therapeutic-grade mRNA involves an in vitro transcription (IVT) process, where template DNA, RNA polymerase, and nucleotides come together to generate high-purity mRNA. But even with this straightforward concept, the process demands extreme precision. Impurities such as double-stranded RNA, abortive transcripts, or incomplete capping can trigger strong immune responses or reduce translation efficiency, making purification a critical step. Techniques such as high-performance liquid chromatography (HPLC), ion-exchange chromatography, and cellulose-based purification are widely used to remove unwanted byproducts. Quality control is equally demanding, requiring analytical methods like capillary electrophoresis, LC-MS, sequencing, and advanced bioassays to verify structural integrity, purity, and functional performance [18-19].

Despite the rapid progress, several challenges persist in mRNA manufacturing and quality assurance. Scaling production while maintaining consistent quality is difficult, especially when transitioning from lab-scale to GMP-level manufacturing. Ensuring batch-to-batch reproducibility, preventing contamination, and maintaining long-term stability are constant hurdles. Additionally, storage remains a major issue, as many mRNA formulations require

ultra-low temperatures to preserve activity [20-21]. Researchers are actively developing thermostable mRNA formats, improved lyophilization processes, and next-gen stabilizers to address these limitations.

Overall, the fundamentals of mRNA therapeutics showcase a delicate balance between molecular biology and pharmaceutical engineering. By mastering the structure, modifications, and manufacturing processes, scientists can produce potent, stable, and safe mRNA molecules. These optimized mRNAs, when paired with next-gen nanoparticles, form the backbone of a rapidly evolving therapeutic revolution poised to reshape global healthcare [22-23].

3. Barriers to Effective mRNA Delivery

Delivering mRNA into the body sounds simple on paper, but in reality it's like sending a fragile glass message through a storm of molecular chaos. The extracellular environment is packed with biological hurdles that can degrade, neutralize, or clear mRNA long before it reaches its target cells. One of the biggest threats is ubiquitous nucleases—enzymes that chop up unprotected RNA within seconds [24-25]. Naked mRNA barely survives in blood or tissues because these enzymes are always on patrol, evolved specifically to eliminate stray genetic material. Beyond enzymatic degradation, the immune system adds another layer of complexity. Pattern-recognition receptors such as TLR3, TLR7, and RIG-I recognize unmodified RNA as a danger signal, triggering inflammation, interferon release, and rapid therapeutic shutdown. This innate immune recognition not only limits the therapeutic effect but can also cause adverse reactions, especially when high doses of mRNA are required. On top of that, the body's clearance systems—particularly renal filtration, liver uptake, and macrophage scavenging—remove circulating biomolecules quickly, giving naked mRNA almost no chance of reaching target tissues [26-27].

Even if mRNA survives the extracellular gauntlet, intracellular delivery introduces a new set of obstacles. Most delivery systems enter cells via endocytosis, meaning the mRNA ends up trapped in endosomes. If it can't escape before these vesicles mature into acidic lysosomes, the mRNA gets degraded. Endosomal escape is one of the biggest bottlenecks in mRNA therapeutics, with only a tiny fraction of internalized nanoparticles successfully releasing cargo into the cytosol. Designing carriers that destabilize endosomal membranes or respond to acidic pH has become a major focus of next-generation delivery strategies. Once mRNA reaches the cytosol, it must avoid secondary degradation by intracellular nucleases and remain structurally intact long enough for ribosomes to translate it into protein. Any delays or inefficiencies at this stage can dramatically reduce therapeutic output [28-29].

Beyond delivery challenges inside the body, mRNA stability during storage is another major barrier limiting widespread adoption. mRNA is inherently unstable, and both the molecule and its formulation are sensitive to temperature, humidity, and pH. Many current mRNA vaccines require strict cold-chain storage at −20°C or even −70°C to prevent hydrolysis and degradation. This dependence on ultra-low temperatures makes global distribution difficult, especially in low-resource regions. Researchers are exploring lyophilization (freeze-drying) to improve

stability, but the process often destabilizes lipid nanoparticles or disrupts mRNA structure unless carefully optimized with cryoprotectants. Achieving room-temperature stability is a major goal for the next wave of mRNA therapeutics, as it would dramatically expand their accessibility, reduce logistical costs, and enable wider deployment [30-31].

Overall, effective mRNA delivery faces a multi-layered set of barriers, from enzymatic degradation and immune activation to intracellular trafficking challenges and demanding storage conditions. Overcoming these hurdles requires sophisticated delivery vehicles capable of protecting, transporting, and releasing mRNA precisely where needed. This is where nanoparticles step in—offering a versatile engineering platform designed to solve these biological challenges head-on [32-33].

4. Nanoparticles for mRNA Delivery: Design Principles

Nanoparticles have become the backbone of mRNA therapeutics precisely because they can be engineered to bypass the numerous biological barriers that block effective delivery. Designing an optimal mRNA-carrying nanoparticle requires attention to a combination of physicochemical and biological factors that determine how the particle behaves in vivo. Size is one of the most critical parameters [34-35]. Particles between 50 and 150 nm generally achieve the best balance of circulation time, cellular uptake, and lymphatic transport. Too small, and they may be cleared rapidly by the kidneys; too large, and they risk being trapped by the spleen or causing inflammation. Shape also influences performance: spherical nanoparticles dominate the field due to their ease of fabrication and predictable behavior, whereas rod-shaped or disc-like particles offer unique interactions with cell membranes but are harder to produce consistently. Surface charge is equally important. Slightly positive or neutral particles enhance cellular uptake while avoiding excessive interactions with serum proteins. Highly cationic carriers bind mRNA efficiently but can be toxic, so ionizable lipids that remain neutral in circulation and become positively charged only inside endosomes have become a key innovation. PEGylation—adding polyethylene glycol to the surface—helps nanoparticles evade the immune system, reduce aggregation, and extend circulation times, although excessive PEG can hinder cellular uptake [35-37].

Biocompatibility and biodegradability are central to safe nanoparticle design. Materials must be non-toxic, must not accumulate in organs, and should degrade into harmless byproducts that the body can eliminate easily. Lipids used in LNPs often mimic natural phospholipids, while biodegradable polymers such as PLGA or PBAEs break down into components already found in metabolic pathways. Ensuring biocompatibility isn't just about safety—it also impacts therapeutic efficacy. If the nanoparticle triggers excessive immune responses or activates complement pathways, it can be cleared quickly, reducing the chances of delivering its mRNA cargo. Therefore, careful tuning of material composition, purity, and surface interactions is essential [38-39].

One of the most valuable features of nanoparticles is their ability to enable controlled release and targeted delivery. Controlled release ensures that mRNA remains protected until the

particle reaches its destination, reducing premature degradation. This can be achieved by engineering carriers that respond to stimuli such as pH, enzymes, or redox conditions. For targeting, nanoparticles can be functionalized with ligands, antibodies, peptides, or aptamers that bind specifically to receptors on certain cells or tissues. This is crucial for applications such as cancer therapy, where directing mRNA to tumor cells improves efficacy while limiting side effects. Passive targeting via the enhanced permeability and retention (EPR) effect also contributes to tumor accumulation, though it varies between patients and tumor types [40-41].

Designing nanoparticles for mRNA delivery is both an art and a science—balancing structure, stability, biocompatibility, and function while navigating complex biological systems. With innovations in microfluidics, computational modeling, and materials engineering, nanoparticle design continues to evolve, bringing us closer to highly precise and personalized mRNA therapeutics that can tackle diseases once thought untreatable [42-43]. Figure 1

Figure 1: A schematic illustration showing the sequential stages of mRNA–nanoparticle transport and cellular processing, including injection of the nanoparticle formulation, systemic circulation, cellular uptake via endocytosis, endosomal escape, cytosolic release of mRNA, and subsequent protein translation.



5. Types of Nanoparticle Platforms for mRNA Delivery

Nanoparticle platforms form the backbone of modern mRNA therapeutics, each offering unique advantages in terms of stability, safety, targeting, and delivery efficiency. Among all platforms, lipid nanoparticles (LNPs) have taken center stage due to their unparalleled success in mRNA vaccines and their impressive ability to protect, transport, and release genetic cargo. LNPs are typically composed of four major components: ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids. Ionizable lipids remain neutral at physiological pH but become positively charged in acidic endosomes, enabling efficient mRNA binding and facilitating endosomal escape through membrane destabilization. Helper lipids support structural integrity and membrane fusion, while cholesterol enhances stability and fluidity [44-45]. PEG-lipids reduce aggregation, prolong circulation, and fine-tune pharmacokinetics. During formulation, LNPs

encapsulate mRNA via rapid electrostatic self-assembly—usually using microfluidics—creating compact particles that protect the fragile RNA from enzymatic degradation and immune detection. Their ability to efficiently promote endosomal escape is the primary reason LNPs remain the gold standard for systemic mRNA delivery [46-47].

Polymeric nanoparticles offer a versatile alternative, especially in applications requiring tailored degradation profiles or reduced immunogenicity. Cationic polymers such as polyethyleneimine (PEI), poly(β-amino esters) (PBAEs), and poly(lactic-co-glycolic acid) (PLGA) have been widely studied. PEI provides strong nucleic acid binding but is limited by cytotoxicity; thus, modern variants rely on lower molecular weight forms or chemical modifications to improve safety. PBAEs stand out for their tunable chemistry, biodegradability, and high transfection efficiency, making them strong candidates for personalized therapies. PLGA, a clinically approved polymer, offers predictable degradation and excellent biocompatibility, although its hydrophobic nature can limit mRNA loading unless combined with cationic components [48-49]. Advances in polymer architecture—such as block copolymers, dendrimers, and crosslinked networks—allow engineers to precisely control charge density, release kinetics, and intracellular trafficking, dramatically boosting both safety and delivery performance [50].

The field is also moving rapidly toward hybrid and bioinspired nanocarriers, which combine the strengths of multiple systems to overcome biological barriers in more sophisticated ways. Lipid–polymer hybrids merge the structural stability of polymers with the fusogenic, endosome-responsive properties of lipids, creating carriers that outperform either class alone. Bioinspired vesicles, such as exosome-mimetic nanoparticles, mimic natural intercellular communication systems and demonstrate excellent biocompatibility and tissue tropism. Some formulations even incorporate cell membrane coatings—derived from cancer cells, immune cells, or stem cells—to create “camouflaged” nanoparticles capable of immune evasion and improved targeting [51-52]. These technologies blur the line between synthetic nanomedicine and natural biology, positioning them as promising platforms for next-generation mRNA therapies in cancer, gene editing, and regenerative medicine.

6. Engineering Strategies for mRNA–Nanoparticle Complexes

Engineering mRNA–nanoparticle complexes is a multi-step process requiring precision at every stage—from nanoparticle fabrication to surface modification, encapsulation efficiency, and computational optimization. Modern fabrication techniques rely heavily on microfluidics, a technology that enables rapid, consistent, and scalable production of nanoparticles with tight control over size, charge, and structure [53-54]. In microfluidic mixers, aqueous mRNA solutions meet lipid or polymer solutions under controlled flow rates, triggering instantaneous self-assembly into uniform nanoparticles. This approach minimizes batch variability, improves encapsulation efficiency, and allows fine-tuning of particle characteristics by adjusting flow ratios and solvent conditions. Microfluidics has become essential for producing GMP-grade LNPs for vaccines and therapeutics [55].

Once nanoparticles are formed, surface functionalization plays a critical role in directing them to specific tissues or cell types. Functional moieties such as targeting ligands, antibodies, peptides, aptamers, or small molecules can be attached to the nanoparticle surface to recognize overexpressed receptors in tumors, immune cells, or diseased tissues. For example, mannose-modified nanoparticles target dendritic cells for vaccine applications, while RGD peptides enhance delivery to tumor vasculature. Surface engineering can modulate not only targeting but also cellular uptake, endosomal progression, and immune interactions, ultimately improving therapeutic outcome [56-57].

Another key engineering challenge is optimizing encapsulation efficiency and particle uniformity. High encapsulation prevents mRNA wastage, reduces dosing requirements, and ensures consistent biological activity. Strategies include tuning lipid:mRNA ratios, adjusting polymer charge density, using ionizable lipids with optimized pKa values, and improving mixing parameters. Particle uniformity—control over size and polydispersity—directly influences pharmacokinetics, biodistribution, and safety. Engineering consistent nanostructures is essential for regulatory approval, clinical reproducibility, and scale-up manufacturing [58-59].

Finally, the integration of computational design and AI-driven optimization is rapidly transforming the field. Machine learning models can predict the ideal lipid structure, polymer composition, or hybrid configuration needed to maximize delivery efficiency while minimizing toxicity. High-throughput screening datasets feed these models, enabling virtual optimization of thousands of nanoparticle formulations in silico before testing the most promising candidates experimentally. Computational approaches also support mRNA sequence optimization, helping design transcripts with reduced immunogenicity and improved stability. The combination of AI-guided materials design and microfluidic fabrication marks the beginning of a new era of smart nanomedicine—fast, customizable, and highly predictive [60-61].

Together, these engineering strategies push mRNA–nanoparticle complexes beyond traditional limitations, setting the stage for safer, more potent, and more targeted mRNA therapies that can reshape everything from vaccines to cancer treatment and gene repair [62].

7. Pharmacokinetics and Biodistribution

Pharmacokinetics and biodistribution determine how effectively mRNA–nanoparticle systems reach their target tissues and how long they remain biologically active. Once administered, these particles undergo several key processes—absorption, circulation, tissue targeting, and clearance—each influenced heavily by nanoparticle design and the body's biochemical environment [63-64]. Absorption varies drastically with the route of administration: intravenous (IV) delivery enables immediate systemic circulation, intramuscular (IM) and subcutaneous injections rely on lymphatic uptake, inhalation targets pulmonary tissues, while oral and transdermal routes must overcome significant biological barriers. After entering circulation, nanoparticles face interactions with proteins, enzymes, and immune cells that govern their ultimate biodistribution. Circulation time, for instance, is strongly influenced by particle size,

PEGylation density, and surface charge. Longer circulation increases the probability of reaching target tissues, but also increases interactions with immune components [65-66].

A critical factor in nanoparticle biodistribution is the protein corona—a layer of adsorbed plasma proteins that coats nanoparticles the moment they encounter blood. This corona acts like a biological "identity card," influencing how the immune system perceives the particle, which receptors it binds to, and how quickly it is cleared. Depending on the corona composition, nanoparticles may be diverted to the liver, spleen, or phagocytic cells, altering therapeutic outcomes. Engineering strategies such as PEGylation or zwitterionic coatings help reduce unwanted protein adsorption, increasing circulation stability and minimizing clearance by macrophages [67].

The route of administration plays a massive role in PK behavior. IV delivery offers the most predictable biodistribution but also exposes nanoparticles to rapid liver and spleen uptake. IM delivery, as used in mRNA vaccines, relies on gradual diffusion and uptake by local immune cells, followed by trafficking to lymph nodes—making it ideal for vaccine responses. Inhaled nanoparticles localize in the lungs, bypass first-pass metabolism, and show promise for treating respiratory diseases. Oral mRNA delivery remains challenging due to enzymatic digestion, while transdermal approaches are still experimental but attractive for their non-invasiveness [68].

Clearance mechanisms determine how long nanoparticles remain functional. Most LNPs accumulate in the liver due to natural filtration processes, where biodegradable lipids are metabolized. Nanoparticles that fail to escape endosomes or that trigger strong immune reactions are cleared more rapidly, reducing therapeutic window. Particle composition, size, charge, and targeting ligands can all be fine-tuned to modulate clearance rates and improve localization to intended tissues. Overall, the intricate dance between nanoparticle engineering and biological forces shapes the pharmacokinetic destiny of mRNA therapeutics, making PK optimization central to clinical success [69-70].

8. Clinical Applications

8.1 Infectious Diseases

mRNA–nanoparticle platforms became global household names after the success of COVID-19 vaccines, but their potential extends far beyond a single pathogen. For infectious diseases, mRNA allows rapid vaccine development by encoding viral antigens that trigger strong immune responses. LNP-based vaccines against RSV, influenza, Zika, and HIV are currently in clinical pipelines. The major advantage is flexibility: when a pathogen mutates, the mRNA sequence can be updated in weeks. Nanoparticles protect the mRNA and ensure effective immune cell targeting, especially dendritic cells, resulting in potent antibody and T-cell responses [71-72]. This speed and modularity make mRNA vaccines ideal for future pandemics, emerging variants, and personalized antiviral strategies.

8.2 Cancer Immunotherapy

Cancer therapy is another domain where mRNA nanoparticles are rewriting the rulebook. Neoantigen vaccines—personalized formulations encoding patient-specific tumor mutations—activate strong cytotoxic T-cell responses, improving tumor recognition and destruction. mRNA can also encode cytokines, immune stimulatory molecules, or checkpoint modulators to reshape the tumor microenvironment. In in situ immunomodulation, nanoparticles deliver mRNA directly into tumors, causing cancer cells to express immune-activating proteins locally, turning "cold" tumors into "hot" ones. Because mRNA does not integrate into DNA and degrades after translation, it enables powerful, temporary immune activation without long-term genomic risk [73-74].

8.3 Genetic and Rare Diseases

Many rare diseases result from missing or dysfunctional proteins, making them ideal candidates for mRNA therapy. mRNA–nanoparticle systems can deliver functional copies of proteins that replace or supplement defective ones. Unlike gene therapy, which permanently modifies DNA, mRNA offers transient expression—safer for conditions requiring controlled dosing. Applications include enzyme replacement in metabolic disorders, delivery of clotting factors for hemophilia, and restoring dystrophin fragments in muscular dystrophy. LNPs ensure mRNA stability and enable tissue-specific delivery, though reaching deep organs like the heart or brain remains an active engineering challenge [75-76].

8.4 Regenerative Medicine

Regenerative medicine is one of the most exciting frontiers for mRNA therapeutics. By encoding growth factors, angiogenic proteins, or transcription factors, mRNA can stimulate tissue repair, promote wound healing, and even reprogram cells. For example, mRNA encoding VEGF has been explored for promoting blood vessel formation in cardiovascular diseases. In tissue engineering, nanoparticles carrying mRNA can direct stem-cell differentiation or enhance scaffold integration [77-78]. Because mRNA expression is temporary, it avoids risks associated with long-term overexpression of potent regenerative factors. This controlled expression window makes mRNA ideal for wound healing, myocardial repair, bone regeneration, and more.

9. Manufacturing, Scale-Up, and Quality Control

Formulating mRNA–nanoparticle complexes at industrial scale is basically the Olympics of pharmaceutical engineering — high-precision, high-stakes, zero room for sloppiness. As these therapeutics move from bench curiosity to global demand (thanks to COVID-19 vaccines setting the bar), manufacturing pipelines must meet strict GMP standards while balancing reproducibility, cost, and global distribution challenges 79-80. GMP-compliant production begins with the synthesis of high-quality in vitro–transcribed (IVT) mRNA, followed by purification steps to eliminate double-stranded RNA contaminants, template DNA residues, and enzymatic by-products. These impurities can trigger unwanted immune responses, making purification just as important as the mRNA sequence itself. Once the mRNA is ready,

microfluidic mixing remains the gold standard for forming lipid nanoparticles (LNPs), ensuring tight control over particle size, encapsulation efficiency, and batch-to-batch consistency — because in nanomedicine, even small deviations can throw off therapeutic performance [81].

Characterizing these particles is a whole different beast. Nanoparticle–mRNA complexes demand multi-layered analytical testing, including dynamic light scattering for size, zeta potential measurements for charge, cryo-electron microscopy for morphology, HPLC and LC–MS for component analysis, and gel electrophoresis to confirm mRNA integrity. The challenge? The system is dynamic: nanoparticles may reorganize or respond to environmental conditions, making real-time, stability-aware analytics essential. Regulatory authorities emphasize orthogonal analytical approaches — meaning you can't rely on one technique alone. And let's be real, this increases the cost and difficulty of QC, but it's unavoidable for products that go straight into human arms.

Storage and transport engineering are another major hurdle. mRNA is notoriously fragile, and lipid nanoparticles hate warm temperatures even more. Traditional deep-cold storage (−70 °C) limited early vaccine distribution, especially in low-resource settings. This pushed the field toward stabilizing strategies like lyophilization (freeze-drying), which removes water without messing up nanoparticle structure. But freeze-drying LNPs is tricky; without optimized cryoprotectants such as sucrose, trehalose, or proprietary polymer blends, particles collapse or fuse. Advanced approaches now explore vitrification, ionizable lipid redesign, and spray-drying technologies to reduce cold-chain dependency. These innovations aim to make future formulations stable at 2–8 °C or even room temperature — the holy grail for global accessibility [82-83].

Scale-up itself introduces engineering constraints. Microfluidics is perfect for R&D but becomes bottlenecked at industrial volume, pushing companies toward parallelization, high-shear mixers, and novel cartridge-based systems that maintain precision at scale. Every step — from raw material sourcing to fill–finish processes — must follow GMP rigor, supported by automated digital monitoring to ensure traceability and regulatory compliance. Ultimately, manufacturing excellence defines whether mRNA nanomedicines will remain elite or become everyday therapeutics for the world [84-85].

10. Safety and Regulatory Considerations

Before mRNA–nanoparticle complexes can reach patients, they must clear a gauntlet of safety and regulatory scrutiny. These therapies blend biologics with nanotechnology, placing them under some of the tightest evaluation frameworks globally. Immunogenicity is the first concern: although nucleoside-modified mRNA reduces innate immune activation, impurities like dsRNA or unoptimized lipid compositions can still trigger cytokine responses. LNPs themselves may cause reactogenicity — fever, fatigue, injection-site inflammation — mostly due to ionizable lipids interacting with immune cells [86]. Regulators expect robust preclinical immune profiling, including complement activation assays, cytokine release studies, and

biodistribution mapping to avoid off-target accumulation in sensitive organs, especially the liver and spleen [87].

Toxicity evaluation is equally critical. Ionizable lipids are engineered to be biodegradable, but their metabolites and long-term effects must be rigorously studied. Repeated dosing, especially for non-vaccine therapeutics, raises concerns about accumulation, lipid overload, or adaptive immune recognition of nanoparticle components. Genotoxicity isn't a major risk because mRNA doesn't enter the nucleus — but regulators still require thorough assessment to calm public and scientific worries. Chronic toxicity studies, reproductive toxicity screening, and multi-dose safety evaluations form essential parts of the pipeline [88].

Long-term safety is especially important because mRNA nanomedicines are moving beyond vaccines into chronic disease management and regenerative medicine. Post-marketing surveillance (pharmacovigilance) becomes the backbone of safety assurance, using real-world data to detect rare adverse events. This includes global reporting networks, digital health monitoring, and AI-driven signal detection systems that flag unusual patterns early. Companies must maintain long-term follow-up for certain therapies, especially those involving repeated administration or novel nanoparticle chemistries [89].

The regulatory landscape is still catching up. Agencies like the FDA, EMA, PMDA, and CDSCO recognize mRNA nanomedicines as a unique class requiring specialized guidance. They emphasize CMC (chemistry, manufacturing, and controls) transparency, detailed nanoparticle characterization, and immunotoxicity documentation. Global harmonization is still in progress — different regions require different assays, slowing down multinational approvals. However, accelerated pathways such as Emergency Use Authorization (EUA) during pandemics demonstrate that flexible regulatory frameworks can coexist with rigorous safety standards [90].

Moving forward, regulators are expected to demand clearer standards for nanoparticle biodegradation, environmental impact, long-term safety tracking, and real-time manufacturing monitoring (PAT tools). The future will lean heavily on digital twins, AI-assisted QC, and adaptive regulatory models. In short, ensuring safety isn't a checkbox — it's an ongoing process that determines whether mRNA nanomedicines truly become the backbone of next-gen healthcare [91].

11. Emerging Innovations

The field of mRNA nanomedicine is evolving at breakneck speed, and the latest innovations are changing the game entirely. One of the most exciting advancements is the rise of self-amplifying mRNA (saRNA) and circular RNA (circRNA) platforms. saRNA contains replicase machinery that allows the message to copy itself inside the cell, leading to dramatically higher protein expression with extremely low doses. This not only reduces manufacturing load but also minimizes toxicity and improves cost-effectiveness. Meanwhile, circRNA brings natural stability advantages because of its closed-loop structure, resisting exonuclease degradation and

prolonging protein translation [92]. These next-gen RNA formats are emerging as powerful alternatives for vaccines, oncology therapeutics, and regenerative medicine.

Smart nanoparticles represent another frontier. Instead of passively releasing cargo, modern delivery systems now respond to physiological stimuli, such as pH, enzymes, temperature, redox gradients, or specific disease biomarkers. Imagine nanoparticles that stay inert in circulation but unleash mRNA only inside tumors or inflamed tissues — that's where the field is heading. Polymers, lipids, hydrogels, and hybrid nanosystems are being engineered to behave like "programmable capsules," ensuring precise spatiotemporal control over RNA translation while minimizing off-target effects [93].

Route-of-administration innovations are equally transformative. Beyond the familiar intramuscular shot, researchers are exploring microneedle patches, which painlessly deposit mRNA nanoparticles into the epidermis, leveraging the abundance of antigen-presenting cells in the skin. Inhalable aerosolized mRNA formulations are gaining traction for lung-targeted treatments, enabling noninvasive therapy for respiratory diseases and even mucosal vaccines. Oral nanocarriers, once considered impossible due to harsh GI conditions, are now feasible thanks to protective polymer coatings and mucoadhesive lipid structures that enable mRNA transport across the intestinal barrier [94].

The integration of artificial intelligence is turbocharging the development pipeline. AI models can optimize mRNA sequences for stability, codon usage, secondary structure, and reduced innate immune recognition. Machine learning assists in designing nanoparticle architectures, predicting biodistribution patterns, and identifying optimal lipid combinations. These in silico approaches dramatically speed up discovery, reduce experimental workload, and push the limits of what's possible with rational nanomedicine design [95].

Together, these innovations point toward a future where mRNA therapies become smarter, more stable, less invasive, and dramatically more personalized.

12. Future Perspectives

The next decade is set to redefine how mRNA therapeutics are applied, produced, and personalized. One major shift will be the maturation of personalized nanomedicine, where mRNA formulations are customized based on individual genetic signatures, tumor mutations, or immune profiles. Personalized neoantigen-based cancer vaccines have already shown remarkable patient-specific responses, and similar concepts will soon extend to autoimmune disorders, metabolic diseases, and regenerative therapies [96].

Another major direction is the convergence of mRNA nanotechnology with gene editing tools like CRISPR–Cas systems. Instead of delivering permanent DNA edits, transient CRISPR mRNA plus guide RNA, delivered via nanoparticles, offer safer genome engineering solutions without long-term insertion risks. This combination could revolutionize therapies for inherited diseases, viral infections, and even age-related decline. Alongside this, immunoengineering

will continue pushing boundaries — enabling in vivo programming of immune cells, mRNA-driven CAR-T therapies, and precision modulation of inflammation.

A key transition will be moving from a vaccine-centric paradigm to diverse therapeutic use cases. COVID-19 showed the world what mRNA can do, but now the field is expanding into protein replacement, oncology, cardiovascular repair, wound healing, fibrosis reversal, and neurodegenerative disease modulation. Multifunctional nanoparticles capable of delivering multiple mRNAs simultaneously will become central to combination therapies, allowing synergistic protein expression patterns [97-98].

However, widespread adoption still faces challenges. Stability remains a bottleneck; achieving durable room-temperature formulations is essential for equitable global distribution. Large-scale manufacturing needs to become cheaper, greener, and more flexible to support diverse therapeutic modalities. Regulatory harmonization across countries must catch up with rapidly evolving technologies to avoid delays in clinical translation. Immunogenicity concerns — especially for repeated therapeutic dosing — will need careful long-term evaluation.

Despite these hurdles, the momentum is undeniable. The integration of nanotechnology, RNA engineering, systems biology, and computational design is paving the way for a future where mRNA-based therapeutics are as routine as conventional small-molecule drugs [99-100].

13. Conclusion

mRNA–nanoparticle complexes represent one of the most transformative advances in modern therapeutics, fusing molecular biology with cutting-edge nanotechnology to unlock entirely new treatment possibilities. Over the past decade, the field has progressed from concept to global clinical success, proving that mRNA can serve as a fast, flexible, and powerful therapeutic modality. Nanoparticles solve the major roadblocks of mRNA delivery — instability, degradation, immune activation, and intracellular trafficking — enabling safe and efficient translation inside target cells.

The review highlights how innovations across chemistry, materials science, and bioengineering have steadily strengthened mRNA therapeutics. From optimized RNA structures and next-gen nanoparticle designs to sophisticated manufacturing platforms and emerging delivery routes, every component of the system continues to evolve. Clinical applications are expanding rapidly, moving from infectious diseases to cancer, genetic disorders, and regenerative medicine. At the same time, safety frameworks, regulatory pathways, and global distribution networks are maturing to support broader therapeutic use.

Nevertheless, challenges remain, including long-term toxicity evaluation, durability of formulations, affordable large-scale production, and the need for harmonized regulatory standards. Addressing these gaps will determine how quickly mRNA nanomedicine transitions from a revolutionary breakthrough to a standard-of-care therapeutic class.Ultimately, engineered mRNA–nanoparticle systems carry the promise of redefining medicine — offering

rapid, programmable, personalized, and multifunctional treatments for complex diseases. With continuing innovation and interdisciplinary collaboration, mRNA nanotherapeutics are poised to power the next generation of precision medicine.

Reference

1. Bray, F.; Laversanne, M.; Weiderpass, E.; Soerjomataram, I. *The ever-increasing importance of cancer as a leading cause of premature death worldwide.* Cancer 2021, 127, 3029–3030.
2. Xia, Z.; Wang, J.; Xia, J.; Wang, M.; Cheng, Z. *Inequality in accessibility of proton therapy for cancers and its economic determinants: A cross-sectional study.* Front Oncol. 2022, 12, 876368.
3. Henson, K.E.; McGale, P.; Darby, S.C.; Parkin, M.; Wang, Y.; Taylor, C.W. *Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer.* Int. J. Cancer 2020, 147, 1437–1449.
4. Kokka, F.; Bryant, A.; Olaitan, A.; Brockbank, E.; Powell, M.; Oram, D. *Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.* Cochrane Database Syst. Rev. 2022, 8, CD010260.
5. Liu, Y.-P.; Zheng, C.-C.; Huang, Y.-N.; He, M.-L.; Xu, W.W.; Li, B. *Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.* MedComm 2021, 2, 315–340.
6. Behranvand, N.; Nasri, F.; Zolfaghari Emameh, R.; Khani, P.; Hosseini, A.; Garssen, J.; Falak, R. *Chemotherapy: A double-edged sword in cancer treatment.* Cancer Immunol. Immunother. 2022, 71, 507–526.
7. Bailly, C.; Thuru, X.; Quesnel, B. *Combined cytotoxic chemotherapy and immunotherapy of cancer: Modern times.* NAR Cancer 2020, 2, zcaa002.
8. Emens, L.A.; Romero, P.J.; Anderson, A.C.; Bruno, T.C.; Capitini, C.M.; Collyar, D.; Gulley, J.L.; Hwu, P.; Posey, A.D., Jr.; Silk, A.W.; et al. *Challenges and opportunities in cancer immunotherapy.* J. Immunother. Cancer 2024, 12, e009063.
9. Zong, Y.; Lin, Y.; Wei, T.; Cheng, Q. *Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.* Adv. Mater. 2023, 35, 2303261.
10. Beck, J.D.; Reidenbach, D.; Salomon, N.; Sahin, U.; Türeci, Ö.; Vormehr, M.; Kranz, L.M. *mRNA therapeutics in cancer immunotherapy.* Mol. Cancer 2021, 20, 69.
11. Taefehshokr, S.; Parhizkar, A.; Hayati, S.; et al. *Cancer immunotherapy: Challenges and limitations.* Pathol. Res. Pract. 2022, 229, 153723.
12. Hu, D.; Zhang, W.; Tang, J.; et al. *Improving safety of cancer immunotherapy via delivery technology.* Biomaterials 2021, 265, 120407.

13. Zou, J.; Zhang, Y.; Pan, Y.; et al. *Advancing nanotechnology for neoantigen-based cancer theranostics.* Chem. Soc. Rev. 2024, 53, 3224–3252.

14. Guo, Y.; Lei, K.; Tang, L. *Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.* Front. Immunol. 2018, 9, 1499.

15. Li, D.-F.; Liu, Q.-S.; Yang, M.-F.; et al. *Nanomaterials for mRNA-based therapeutics.* Bioeng. Transl. Med. 2023, 8, e10492.

16. Karim, M.E.; Haque, S.T.; Al-Busaidi, H.; et al. *Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment.* Arch. Pharmacal Res. 2022, 45, 865–893.

17. Shi, Y.; Shi, M.; Wang, Y.; You, J. *Progress and prospects of mRNA-based drugs.* Signal Transduct. Target. Ther. 2024, 9, 322.

18. Wilson, B.; Geetha, K.M. *Lipid nanoparticles in mRNA vaccines.* J. Drug Deliv. Sci. Technol. 2022, 74, 103553.

19. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. *Lipid nanoparticles for mRNA delivery.* Nat. Rev. Mater. 2021, 6, 1078–1094.

20. Kon, E.; Ad-El, N.; Hazan-Halevy, I.; Peer, D. *Targeting cancer with mRNA–lipid nanoparticles.* Nat. Rev. Clin. Oncol. 2023, 20, 739–754.

21. Chen, J.; Ye, Z.; Huang, C.; et al. *LNP-mediated lymph node–targeting mRNA vaccine.* PNAS 2022, 119, e2207841119.

22. Kim, K.H.; Bhujel, R.; Maharjan, R.; et al. *Biophysical characterization of siRNA-loaded LNPs.* Eur. J. Pharm. Biopharm. 2023, 190, 150–160.

23. Gilbert, J.; Sebastiani, F.; Arteta, M.Y.; et al. *Evolution of LNP structure for nucleic acid delivery.* J. Colloid Interface Sci. 2024, 660, 66–76.

24. Witten, J.; Raji, I.; Manan, R.S.; et al. *AI-guided design of LNPs for pulmonary gene therapy.* Nat. Biotechnol. 2024, 1–10.

25. Kumari, K.; Singh, H.R.; Sampath, M.K. *AI-optimized LNPs for amoxicillin delivery.* Biologia 2025, 80, 133–148.

26. Maharjan, R.; Kim, K.H.; Lee, K.; et al. *Machine learning optimization of mRNA-LNP vaccines.* J. Pharm. Anal. 2024, 14, 100996.

27. Alejo, T.; Toro-Córdova, A.; Fernández, L.; et al. *Freeze-drying for mRNA-LNP stability.* Int. J. Mol. Sci. 2024, 25, 10603.

28. Kommineni, N.; Butreddy, A.; Sainaga Jyothi, V.G.S.; Angsantikul, P. *Freeze-drying for immunoengineering products.* iScience 2022, 25, 105127.

29. Kamiya, M.; Matsumoto, M.; Yamashita, K.; et al. *Stability study of mRNA-LNPs.* Pharmaceutics 2022, 14, 2357.

30. Reinhart, A.-G.; Osterwald, A.; Ringler, P.; et al. *Shelf-life stability of mRNA-LNPs.* Mol. Pharm. 2023, 20, 6492–6503.

31. Viganò, M.; La Milia, M.; Grassini, M.V.; et al. *Hepatotoxicity of small molecule kinase inhibitors.* Cancers 2023, 15, 1766.

32. Ramadan, E.; Ahmed, A.; Naguib, Y.W. *Advances in mRNA LNP-based cancer vaccines.* J. Pers. Med. 2024, 14, 1092.

33. Mohan, G.; T P, A.H.; A J, J.; et al. *Recent advances in radiotherapy and side effects.* J. Basic Appl. Zool. 2019, 80, 14.

34. Zhong, L.; Li, Y.; Xiong, L.; et al. *Small molecules in targeted cancer therapy.* Signal Transduct. Target. Ther. 2021, 6, 201.

35. Barazzuol, L.; Coppes, R.P.; van Luijk, P. *Radiotherapy-induced side effects.* Mol. Oncol. 2020, 14, 1538–1554.

36. Abu-Alhaija, D.; Bakas, T.; Shaughnessy, E.; Miller, E. *Factors influencing chemotherapy exposure among nurses.* Workplace Health Saf. 2023, 71, 212–227.

37. Yamamoto, S.; Sanefuji, M.; Inoue, H.; et al. *Parental occupational exposure to anticancer drugs.* Early Hum. Dev. 2025, 201, 106195.

38. Leso, V.; Sottani, C.; Santocono, C.; et al. *Exposure to antineoplastic drugs in workplaces.* IJERPH 2022, 19, 3737.

39. Maharjan, R.; Lee, J.C.; Lee, K.; et al. *AI and ML in biopharma manufacturing.* J. Pharm. Investig. 2023, 53, 803–826.

40. Maharjan, R.; Hada, S.; Lee, J.E.; et al. *AI-assisted mRNA-LNP bioprocessing.* Int. J. Pharm. 2023, 640, 123012.

41. Yuan, Y.; Wu, Y.; Cheng, J.; Yang, K.; Xia, Y.; Wu, H.; Pan, X. Applications of artificial intelligence to lipid nanoparticle delivery. *Particuology* 2024, 90, 88–97.

42. Ou, Y.; Zhao, J.; Tripp, A.; Rasoulianboroujeni, M.; Hernández-Lobato, J.M. A Deep Generative Model for the Design of Synthesizable Ionizable Lipids. *arXiv* 2024, arXiv:2412.00928.

43. Jain, A.; Praveena, K.; Anandhi, R.; Kumar, S.; Alabdely, H.; Srivastava, A.P. Blockchain and Machine Learning for Automated Compliance in Regulatory Technology. In *Proceedings of the 2024 IEEE 13th International Conference on Communication Systems and Network Technologies (CSNT)*, Jabalpur, India, 6–7 April 2024; pp. 1–6.

44. Manee, V.; Baratti, R.; Romagnoli, J.A. Learning to navigate a crystallization model with deep reinforcement learning. *Chem. Eng. Res. Des.* 2022, 178, 111–123.

45. Hunt, P.; Hosseini-Gerami, L.; Chrien, T.; Plante, J.; Ponting, D.J.; Segall, M. Predicting pKa using semi-empirical quantum mechanics and radial basis function methods. *J. Chem. Inf. Model.* 2020, 60, 2989–2997.

46. Luo, W.; Zhou, G.; Zhu, Z.; Ke, G.; Wei, Z.; Gao, Z.; Zheng, H. Uni-pKa: Accurate pKa prediction through protonation ensemble modeling. *ChemRxiv* 2023, 1–27.

47. Moayedpour, S.; Broadbent, J.; Riahi, S.; Bailey, M.; Thu, H.V.; Dobchev, D.; et al. Representations of lipid nanoparticles using large language models for transfection efficiency prediction. *Bioinformatics* 2024, 40, btae342.

48. Dong, S. Machine Learning Modelling in Predicting and Optimizing PLGA Nanoparticle Encapsulation Efficiency and Therapeutic Efficacy. Master's Thesis, University of Waterloo, 2023.

49. McDonnell, A.; Van Exan, R.; Lloyd, S.; Subramanian, L.; Chalkidou, K.; La Porta, A.; et al. COVID-19 Vaccine Predictions: Mathematical Modelling and Expert Estimates; Center for Global Development: Washington, DC, USA, 2020.

50. Ye, Z.; Ouyang, D. Opportunities and Challenges of Artificial Intelligence (AI) in Drug Delivery. In *Exploring Computational Pharmaceutics—AI and Modeling in Pharma 4.0*; Wiley: Hoboken, NJ, USA, 2024; pp. 10–58.

51. Chaudhary, N.; Weissman, D.; Whitehead, K.A. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. *Nat. Rev. Drug Discov.* 2021, 20, 817–838.

52. Biscans, A.; Ly, S.; McHugh, N.; Cooper, D.A.; Khvorova, A. Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo. *J. Control. Release* 2022, 349, 831–843.

53. Kang, D.D. Strategies to Design and Refine Lipid Nanoparticles for Functional mRNA Delivery. Ph.D. Thesis, The Ohio State University, 2025.

54. Mrksich, K.; Padilla, M.S.; Mitchell, M.J. Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. *Adv. Drug Deliv. Rev.* 2024, 214, 115446.

55. Xu, Y.; Golubovic, A.; Xu, S.; Pan, A.; Li, B. Rational design and combinatorial chemistry of ionizable lipids for RNA delivery. *J. Mater. Chem. B* 2023, 11, 6527–6539.

56. Rietwyk, S.; Peer, D. Next-generation lipids in RNA interference therapeutics. *ACS Nano* 2017, 11, 7572–7586.

57. Kukreja, V.; Dogra, A.; Kaushal, R.K.; Mehta, S.; Vats, S.; Goyal, B. Dual U-Net + Federated Learning for brain tumor analysis. *Curr. Med. Imaging* 2024, 20, e15734056312765.

58. Tan, Y.N.; Lam, P.D.; Tinh, V.P.; Le, D.-D.; Nam, N.H.; Khoa, T.A. Federated learning with deep segmentation + GMM for breast cancer tumors. *IEEE Access* 2024, 12, 94231–94249.

59. Shiri, I.; Sadr, A.V.; Amini, M.; Salimi, Y.; Sanaat, A.; Akhavanallaf, A.; et al. Federated PET image segmentation across institutions. *Clin. Nucl. Med.* 2022, 47, 606–617.

60. Ndemazie, N.B. Synthesis and Biological Evaluation of Novel 5-FU Analog for Pancreatic Cancer. Ph.D. Thesis, Florida A&M University, 2023.

61. Guo, Z.; He, B.; Jin, H.; Zhang, H.; Dai, W.; Zhang, L.; et al. Targeting efficiency of RGD-modified nanocarriers with variable ligand intervals. *Biomaterials* 2014, 35, 6106–6115.

62. Gao, X.J.; Ciura, K.; Ma, Y.; Mikolajczyk, A.; Jagiello, K.; Wan, Y.; et al. Integrating machine learning & molecular modeling for drug delivery nanocarriers. *Adv. Mater.* 2024, 36, 2407793.

63. Foglietta, F.; Serpe, L.; Canaparo, R. 3D cancer models + stimuli-responsive nanosystems. *Cells* 2021, 10, 3295.

64. Perche, F.; Biswas, S.; Torchilin, V. Stimuli-Sensitive Polymeric Nanomedicines. In *Handbook of Polymer Pharmaceutical Technologies* 2015; pp. 311–344.

65. Wang, Y.; Ukwattage, V.; Xiong, Y.; Such, G.K. Improving endosomal escape of polymeric nanoparticles. *Mater. Horiz.* 2025, 12, 3622–3632.

66. Fu, L.; Zhang, Y.; Farokhzad, R.A.; Mendes, B.B.; Conde, J.; Shi, J. Passive nanoparticles for organ-selective systemic delivery. *Chem. Soc. Rev.* 2023, 52, 7579–7601.

67. Wu, J.; Zhou, X.; Tsang, C.Y.; Mei, Q.; Zhang, Y. Bioengineered nanomaterials for dynamic diagnostics in vivo. *Chem. Soc. Rev.* 2025, 54, 5470–5515.

68. Sun, Y.; Miao, D.; Zeng, Z.; Li, X.; Pu, Y.; Liu, L.; et al. Micro/Nanoneedle arrays for intracellular biomacromolecule delivery. *Adv. Funct. Mater.* 2025, 2422234.

69. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-dimensional docking for receptor flexibility. *J. Med. Chem.* 2009, 52, 397–406.

70. Ramalho, M.J.; Loureiro, J.A.; Coelho, M.A.; Pereira, M.C. Transferrin receptor-targeted nanocarriers for glioblastoma. *Pharmaceutics* 2022, 14, 279.

71. Maccallum, R. Automated Ligand Design using Deep Q-Learning. Master's Thesis, University of Cape Town, 2022.

72. Cegarra, C.; Cameron, B.; Chaves, C.; Dabdoubi, T.; Do, T.-M.; Genêt, B.; et al. Identifying new antibody delivery targets in brain via integrins. *PLoS ONE* 2022, 17, e0274667.

73. Mehdizadeh, S.; Mamaghani, M.; Hassanikia, S.; Pilehvar, Y.; Ertas, Y.N. Exosome-powered neuropharmaceutics. *J. Nanobiotechnol.* 2025, 23, 329.

74. Li, Y.; Ladd, Z.; Xiong, Z.; Bui-Linh, C.; Paiboonrungruang, C.; Subramaniyan, B.; et al. NRF2 & lymphatic metastasis in esophageal carcinoma. *Cancers* 2025, 17, 1853.

75. Xu, H.; Xu, Q.; Cong, F.; Kang, J.; Han, C.; Liu, Z.; et al. Vision transformers for histopathology. *IEEE Rev. Biomed. Eng.* 2023, 17, 63–79.

76. Lodewijk, I.; Dueñas, M.; Paramio, J.M.; Rubio, C. CD44v6, STn & O-GD2 as tumor antigens. *Front. Immunol.* 2023, 14, 1272681.

77. Panda, S.; Eaton, E.J.; Muralikrishnan, P.; Stelljes, E.M.; Seelig, D.; Leyden, M.C.; et al. Amine type in polymer micelles determines mRNA binding & lung delivery. *JACS Au* 2025, 5, 1845–1861.

78. Gao, H. Integrated in Silico Formulation Design of Lipid-Based Delivery Systems. Ph.D. Thesis, University of Macau, 2022.

79. Wang, Z.; Kelley, S.O. Microfluidics for adoptive cell therapy optimization. *Nat. Biomed. Eng.* 2025, 9, 803–821.

80. Navaneeth, A.G.; Karthikeyan, S. Aptamer-functionalized nanoparticles for cancer therapy. *RSC Pharm.* 2024, 1, 879–903.

81. Shi, Y.; Li, X.; Li, Z.; Sun, J.; Gao, T.; Wei, G.; et al. Nano-formulations in disease therapy. *J. Nanobiotechnol.* 2025, 23, 396.

82. Touramanidou, L.; Gurung, S.; Cozmescu, C.A.; Perocheau, D.; Moulding, D.; Finn, P.F.; et al. Clodronate improves lentiviral liver transduction. *Cells* 2024, 13, 1979.

83. Zhou, Y.; Wang, X.; Zhang, D.; Cui, H.; Tian, X.; Du, W.; et al. Biological carrier–mediated nanomedicine hitchhiking strategy. *Adv. Sci.* 2025, 12, 2504672.

84. Bitounis, D.; Jacquinet, E.; Rogers, M.A.; Amiji, M.M. Strategies to reduce mRNA drug toxicity. *Nat. Rev. Drug Discov.* 2024, 23, 281–300.

85. Gharatape, A.; Amanzadi, B.; Mohamadi, F.; Rafieian, M.; Faridi-Majidi, R. Stimuli-responsive nanocarriers for cancer immunotherapy. *Nanomedicine* 2024, 19, 2655–2678.

86. Dermawan, D.; Alotaiq, N. AI reshaping drug discovery timelines. *Pharmaceuticals* 2025, 18, 981.

87. Zhou, K.; Liu, Y.; Tang, C.; Zhu, H. Pancreatic cancer: Pathogenesis & clinical studies. *MedComm* 2025, 6, e70162.

88. Xin, Q.; Chen, Y.; Sun, X.; Li, R.; Wu, Y.; Huang, X. CAR-T therapy for ovarian cancer. *Biochem. Pharmacol.* 2024, 226, 116349.

89. Abbasi Dezfouli, S.; Rajendran, A.P.; Claerhout, J.; Uludag, H. Nanomedicines for breast cancer therapy. *Biomolecules* 2023, 13, 1559.

90. Drewa, J.; Lazar-Juszczak, K.; Adamowicz, J.; Juszczak, K. Periprostatic adipose tissue in prostate cancer. *Cancers* 2025, 17, 372.

91. Balestra, M. EGFR Non-Clathrin Endocytosis Regulation. Ph.D. Thesis, Università degli Studi di Milano, 2025.

92. Chen, Z.; Yang, Y.; Qiu, X.; Zhou, H.; Wang, R.; Xiong, H. Crown-like biodegradable lipids for lung-selective mRNA delivery. *J. Am. Chem. Soc.* 2024, 146, 34209–34220.

93. Kucińska, M.K. Receptor-Mediated Lysosomal Clearance of ER & ONM. Ph.D. Thesis, ETH Zurich, 2024.

94. Sikder, R.; Zhang, H.; Gao, P.; Ye, T. Machine learning for predicting cytotoxicity of disinfection byproducts. *J. Hazard. Mater.* 2024, 469, 133989.

95. Marciniec, K.; Nowakowska, J.; Chrobak, E.; Bębenek, E.; Latocha, M. Quinolinesulfonamides–Triazole hybrids with anticancer activity. *Molecules* 2024, 29, 3158.

96. Li, R.; Zhu, M.; Hu, X.; Chen, J.; Yu, F.; Barth, S.; et al. Overcoming endosomal/lysosomal barriers for siRNA delivery. *Chin. Chem. Lett.* 2024, 36, 110736.

97. Bloom, K.; van den Berg, F.; Arbuthnot, P. Self-amplifying RNA vaccines. *Gene Ther.* 2021, 28, 117–129.

98. Odunze, U.; Rustogi, N.; Devine, P.; Miller, L.; Pereira, S.; Vashist, S.; et al. RNA-encoded peptide barcodes for in vivo delivery screening. *Nucleic Acids Res.* 2024, 52, 9384–9396.

99. Wang, W.; Chen, K.; Jiang, T.; Wu, Y.; Wu, Z.; Ying, H.; et al. AI-driven design of ionizable lipids for mRNA delivery. *Nat. Commun.* 2024, 15, 10804.

100. Tani, H. Advances and Prospects in RNA Drug Development. *Int. J. Mol. Sci.* 2024, 25, 12284.